| scholarly article | Q13442814 |
| P2093 | author name string | Qing Li | |
| Peng Yuan | |||
| Yang Luo | |||
| Ying Fan | |||
| Binghe Xu | |||
| Jiayu Wang | |||
| Fei Ma | |||
| Pin Zhang | |||
| Qiao Li | |||
| Ruigang Cai | |||
| Shanshan Chen | |||
| Die Sang | |||
| P2860 | cites work | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 | Q30543788 | ||
| Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). | Q30873972 | ||
| Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies | Q33593016 | ||
| Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study | Q34493998 | ||
| Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Q35130819 | ||
| Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas | Q35586783 | ||
| Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer | Q35780969 | ||
| Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania | Q35805644 | ||
| Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades | Q36306315 | ||
| Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients | Q36609527 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
| Estimation and projection of the national profile of cancer mortality in China: 1991-2005 | Q36694281 | ||
| The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study | Q36807110 | ||
| Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry | Q36892788 | ||
| Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis | Q36916147 | ||
| Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer | Q37198196 | ||
| Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to ne | Q37302415 | ||
| An international Ki67 reproducibility study | Q37463125 | ||
| Challenges in defining predictive markers for response to endocrine therapy in breast cancer | Q37630581 | ||
| Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients | Q37898842 | ||
| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis | Q38188183 | ||
| Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies | Q38263152 | ||
| An international study to increase concordance in Ki67 scoring | Q39037175 | ||
| Estimates of cancer incidence in China for 2000 and projections for 2005. | Q40451705 | ||
| Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors | Q42468897 | ||
| The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes | Q42511189 | ||
| Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment | Q45099316 | ||
| Neoadjuvant treatment of breast cancer. | Q45140936 | ||
| The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. | Q46373510 | ||
| Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial | Q46786144 | ||
| Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. | Q46966638 | ||
| Breast cancer as a global health concern. | Q50560105 | ||
| Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. | Q51018339 | ||
| Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. | Q53247398 | ||
| Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. | Q54516956 | ||
| Effect of preoperative chemotherapy on the outcome of women with operable breast cancer | Q77093352 | ||
| Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis | Q81353372 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e3518 | |
| P577 | publication date | 2016-05-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population | |
| P478 | volume | 95 |
| Q52584340 | 18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients. |
| Q57298998 | Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations |
| Q38779230 | Association Between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negative Breast Cancer |
| Q64893434 | Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki-67 in Chinese breast cancer patients: A retrospective study of 525 patients. |
| Q41521411 | Effect of therapeutic care for treating fatigue in patients with breast cancer receiving chemotherapy |
| Q49486164 | Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis |
| Q38673841 | Potential prognostic value of clinical characteristics, hormone status and major depressive disorder in breast cancer |
| Q47104704 | Prognostic significance of lymphatic vessel invasion diagnosed by D2-40 in Chinese invasive breast cancers |
| Q88468281 | Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas |
Search more.